Heterocyclic TAAR1 Agonists for Safer CNS Neurotransmission Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TAAR1 agonists for treating psychiatric disorders like schizophrenia, depression, Parkinson's disease psychosis, and ADHD have safety concerns and limited efficacy, necessitating the development of a safer and more effective compound.
Innovation Solution
Development of heterocyclic compounds as TAAR1 agonists with specific structural variations, including different combinations of A1, A2, R1, R2, Z1, Z2, Z3, Z4, and Z5, which can act as pharmaceutically acceptable salts, stereoisomers, or prodrugs, to modulate neurotransmission and reduce adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amphetamine is used as a TAAR1 agonist for treating ADHD, then therapeutic efficacy is achieved, but strong excitability to the central nervous system causes adverse reactions such as insomnia, restlessness, delusion and hallucination
Solution Approach 1:
The patent applies parameter changes by developing novel heterocyclic compound structures with specific molecular characteristics (formula IA with defined substituents A1, A2, R1, R2) that modify the pharmacological properties. These structural parameter changes enable the compound to activate TAAR1 receptors while reducing off-target effects on other neurotransmitter systems, thereby maintaining therapeutic efficacy while minimizing adverse reactions like insomnia and hallucination
Solution Approach 2:
The patent employs composite material principles by creating a complex heterocyclic molecular structure that combines multiple functional groups and structural elements. This composite structure allows the compound to selectively interact with TAAR1 receptors while avoiding excessive activation of other CNS pathways, thus achieving a balance between therapeutic benefit and safety profile
2Object-affected harmful factors
If RG-7906, RO-5263397, or SEP-363856 are used as TAAR1 selective agonists, then safety is improved compared to amphetamine, but clinical progression is limited with some trials paused or stopped
Solution Approach 1:
The patent applies parameter changes by optimizing the heterocyclic compound structure (formula IA) to achieve ideal pharmacokinetic and pharmacodynamic parameters. The specific substituent patterns and molecular weight range are designed to enhance brain penetration and receptor selectivity, addressing the clinical efficacy limitations observed with previous compounds while maintaining an improved safety profile
3Duration of action of stationary object
If long-term administration of amphetamine is performed, then therapeutic effects are maintained, but adverse reactions such as insomnia, restlessness, delusion and hallucination increase
Solution Approach 1:
The patent applies parameter changes by designing a heterocyclic compound with optimized metabolic stability and half-life characteristics. The molecular structure is engineered to provide sustained TAAR1 activation without accumulating to toxic levels, enabling long-term therapeutic effect while reducing cumulative adverse effects through controlled metabolism and excretion
Data Source
AI summary
Provided are a heterocyclic compound used as a TAAR1 agonist, a preparation method of the compound, a pharmaceutical composition containing the compound, and a use of the compound as a TAAR1 agonist in preventing and/or treating various CNS-related diseases. Each substituent in the general formula (IA) is the same as defined in the description.